Advanced Search

    column
    Co-Amplification, Double Targeting, More Efficacious
    KANG Jin, YANG Jin-ji
    2017, 17(3): 129-129. DOI: 10.12019/j.issn.1671-5144.2017.03.001
    Abstract PDF
    The Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors Cancer Appear Again
    LI An-na
    2017, 17(3): 130-131. DOI: 10.12019/j.issn.1671-5144.2017.03.002
    Abstract PDF
    Small but Unnegligible Groups in The Era of Precision Medicine
    KANG Jin, YANG Jin-ji
    2017, 17(3): 132-132. DOI: 10.12019/j.issn.1671-5144.2017.03.003
    Abstract PDF
    Targeting New Star: NTRK1 Fusion
    WANG Wen-xian, XU Chun-wei, CHEN Gang
    2017, 17(3): 133-133. DOI: 10.12019/j.issn.1671-5144.2017.03.004
    Abstract PDF
    Explore, Progress, Confused: Triple Negative Breast Cancer Therapy in 2017
    LIAO Ning
    2017, 17(3): 134-139. DOI: 10.12019/j.issn.1671-5144.2017.03.005
    Abstract PDF
    The Interpretation of CALGB 40603 Trial: The Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Chemotherapy Improve Pathologic Complete Response Rates in StageⅡto Ⅲ Triple Negative Breast Cancer
    Reviewers： YAO He-rui, You Kai-yun, WANG Ying, Literature Co-workers： YU Yun-fang
    2017, 17(3): 140-145. DOI: 10.12019/j.issn.1671-5144.2017.03.006
    Abstract PDF
    The Safety and Therapeutic Effect Evaluation of Pembrolizumab in Patients with Advanced PD-L1 Positive Triple Negative Breast Cancer
    WANG Xian-ming, TANG Jing
    2017, 17(3): 146-149. DOI: 10.12019/j.issn.1671-5144.2017.03.007
    Abstract PDF
    Neoadjuvant Carboplatin in Patients with Triple Negative Early Breast Cancer Can Improve The Pathological Complete Response Rate
    PANG Dan-mei, WEN Ling-zhu
    2017, 17(3): 150-152. DOI: 10.12019/j.issn.1671-5144.2017.03.008
    Abstract PDF
    I-SPY2 Provides The New Trend of Breast Cancer Clinical Trials
    XU Rui-lian, REN Chong-yang
    2017, 17(3): 153-154. DOI: 10.12019/j.issn.1671-5144.2017.03.009
    Abstract PDF
    Clinical Research of Severe Drug Eruption with Combined Different Dose Intravenous Immunoglobulin and Glucocorticoid
    WANG Hong-yan, WANG Qun
    2017, 17(3): 155-158. DOI: 10.12019/j.issn.1671-5144.2017.03.010
    Abstract PDF
    The Clinical Analysis of Protecting Side Branch with A Small Balloon in Treating Coronary Bifurcation Lesion
    GONG Hui, HUANG Ding, ZHANG Xiang-yang
    2017, 17(3): 159-162. DOI: 10.12019/j.issn.1671-5144.2017.03.011
    Abstract PDF
    Effects of Glucagon-Like Peptide-1 Analog on CDAA Diet-Induced Models of Nonalcoholic Fatty Liver Fibrosis in Rats
    CHEN Xin-qun, XU Li-shu, LI Dong-feng, DENG Wei-ping
    2017, 17(3): 163-170. DOI: 10.12019/j.issn.1671-5144.2017.03.012
    Abstract PDF
    Function of The Regional Blockade with Ropivacaine on The Enhanced Recovery after Surgery of Pediatric Patients with Hernias
    YANG Hui-ju, YU Dong-nan, MA Jue, HU Shi-xiong, ZHANG Deng-wen, WANG Sheng
    2017, 17(3): 171-174. DOI: 10.12019/j.issn.1671-5144.2017.03.013
    Abstract PDF
    Hypothesis Test Based on Re-Sampling for Meta-Analysis of Gene Expression Profiling Studies Application
    HE Jie-yu, SUN Jin-fang, WANG Li-na, MIN Jie, YU Xiao-jin
    2017, 17(3): 175-179. DOI: 10.12019/j.issn.1671-5144.2017.03.014
    Abstract PDF
    Tolerance and Urinary Bladder Toxicity Study of Phenethyl Isothiocyanate Capsules at Multiple Doses in Human Body
    HE Guo-dong, MAI Li-ping, GU Liang, CHEN Ju-ying, CHENG Zhi-wei, GUO Lan, YANG Min
    2017, 17(3): 180-183. DOI: 10.12019/j.issn.1671-5144.2017.03.015
    Abstract PDF
    A Literature Review of Radiogenomics Predicting Tumor Responses to Neoadjuvant Chemotherapy in Breast Cancer
    XIONG Qian-qian, WANG Kun
    2017, 17(3): 184-189. DOI: 10.12019/j.issn.1671-5144.2017.03.016
    Abstract PDF
    Diagnosis and Treatment of Juvenile Myelomonocytic Leukemia
    ZHANG Jin-fang, LIN Yu-deng
    2017, 17(3): 190-192. DOI: 10.12019/j.issn.1671-5144.2017.03.017
    Abstract PDF